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Objectives Because post-transcriptional mechanisms modulate levels of p16 (encoded by CDKN2A) and p15 (encoded by
CDKN2B), we tested whether interferon- regulates the expression of these proteins and the effect of the 9p21
genotype.
Background The mechanism whereby the common variant at chromosome 9p21.3 confers risk for coronary artery disease
(CAD) remains uncertain. A recent report proposed that 9p21.3 confers differential activation of adjacent genes
in response to interferon-, and reported that mRNA levels of CDKN2B are reduced in response to interferon-.
Methods Human umbilical vein endothelial cells (HUVECs), aortic smooth muscle cells, HeLa cells, HEK293 cells, and 16
human lymphoblastoid cell lines, all genotyped for the 9p21.3 locus, were treated with interferon- and ana-
lyzed by immunoblot.
Results In all cells tested—except HUVECs where expression was not modulated by interferon-—regardless of 9p21.3
genotype, interferon- increased the expression of p16 and p15. Northern blot analysis confirmed that
interferon- has little effect on mRNA levels of CDKN2A and CDKN2B.
Conclusions The 9p21.3 risk genotype does not affect the activation of cyclin-dependent kinase inhibitors p15 and p16 by
interferon-. Thus, another mechanism is likely to account for the CAD risk associated with this locus. (J Am
Coll Cardiol 2013;61:143–7) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1020s
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aThe common genetic variant located in the vicinity of the
genes encoding the cyclin-dependent kinase inhibitors p15
(CDKN2B) and p16/ARF (CDKN2A) on the short arm of
chromosome 9 at 9p21.3 contributes to the risk of CAD by
an unknown mechanism that is independent of known risk
factors (1–3). 9p21.3 associates with the severity of coronary
atherosclerosis in a risk allele–dosage-specific manner (4),
recently confirmed by others (5). Among cases with
coronary artery disease (CAD), 9p21.3 does not associate
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accepted August 9, 2012.with myocardial infarction (4), suggesting that it pro-
motes atherosclerosis rather than thrombosis.
The 9p21.3 risk locus consists of many tightly linked
single nucleotide polymorphisms (SNPs) that cover an area
of about 58,000 bp. Whether a single SNP at this locus is
functional, or whether several SNPs have a functional effect,
remains controversial. We identified enhancer sequences
within the 9p21.3 region, and in particular, we found that
the SNP rs1333045 conferred differential enhancer activity
(6). A recent study that ablated the homologous sequences
in the mouse genome observed markedly reduced expression
of CDKN2A and CDKN2B mRNA (7), confirming the
existence of regulatory sequences in this region. Another
recent report provided evidence that the SNP rs10757278 at
the 9p21.3 CAD risk locus disrupts a STAT1-responsive
sequence and confers differential activation of adjacent
genes in response to interferon- (8). Thus, these authors
uggested that inability to up-regulate p15 and p16 would
romote cellular proliferation and atherosclerosis. However,
he evidence they provided to support this suggestion
ppeared to contradict their hypothesis. For example, quan-
itative polymerase chain reaction (PCR) measured reduced
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to interferon-y in HeLa cells and
human umbilical vein endothelial
cells (HUVECs), both heterozy-
gous for the rs10757278 SNP (8).
However, the single STAT-1–
responsive allele in heterozygous
cells should have been activated by
interferon-y. Moreover, altered
mRNA expression does not always
translate to altered protein levels. For
example, transforming growth
factor- markedly elevates p15 pro-
tein levels but barely increases
mRNA levels (9), whereas the
icro-RNA miR-24 suppresses translation of the p16 mRNA
ithout affecting mRNA levels (10). In light of these post-
ranscriptional mechanisms, and to confirm whether or not an
nterferon-–dependent mechanism operates at the 9p21.3 risk
ocus, we re-examined the association of the 9p21.3 genotypes
ith the response of p15 and p16 to interferon- at the protein
evel in different cell lines.
aterials and Methods
ell cultures. Human primary aortic smooth muscle cells
HAoSMCs) were purchased with culture medium from
ell Applications (San Diego, California); HUVECs were
btained from Lonza (Allendale, New Jersey), and cultured
s recommended; and lymphoblastoid cells (LCLs) (n 16)
ere selected for their 9p21 genotype and purchased from
he Coriell Institute for Medical Research (Camden, New
ersey), and cultured in RPMI Medium 1640 (Invitrogen,
urlington, Ontario, Canada). Recombinant human
nterferon- was purchased from R&D Systems (Minneap-
lis, Minnesota).
enotyping. DNA from HeLa, HUVECs, HEK293 cells,
nd LCLs was genotyped for the 9p21.3 risk locus by PCR
nd sequencing. A DNA fragment containing SNP
s1333048 was obtained using primers 5=-TGG CTA TAA
TG CCT TTG GC-3= and 5=-CCA TAT ATC TTG
TT ACC TCT GCG-3=, and another fragment contain-
ng rs10757278 and rs10811656 was obtained using primers
=-TTG GAA CTG AAC TGA GGC CAG ACA-3= and
=-TAG ACT CCA CGC TGT TCC CAA GTA-3=.
AoSMCs were genotyped on Affymetrix Axiom arrays
Affymetrix, Santa Clara, California).
rocessing of cells for immunoblotting. Cells were lysed
n RIPA buffer (4.25 mmol/l Tris [pH 8.0], 135 mmol/l
aCl, 1% IGEPAL CA-630, 1% SDS 0.5% deoxycholate)
ontaining protease and phosphatase inhibitors (Roche
olecular Systems, Branchburg, New Jersey). Lysate pro-
ein concentrations were measured by Bradford assay before
DS-PAGE and immunoblot analysis.
ntibodies and immunoblot analyses. Mouse anti-p16
Abbreviations
and Acronyms
CAD  coronary artery
disease
HAoSMC  human primary
aortic smooth muscle cells
HUVEC  human umbilical
vein endothelial cell
LCL  lymphoblastoid cell
PCR  polymerase chain
reaction
SNP  single nucleotide
polymorphismsc-9968) and anti-p15 (sc-171798) antibodies were pur-hased from Santa Cruz Biotechnology (Santa Cruz, Cali-
ornia), antibody to p14 (clone 4C6/4) was from EMD
illipore (Temecula, California), antibody to phosphory-
ated serine 727 (p-Ser 727) of Stat1 from Cell Signaling
echnology (Danvers, Massachusetts), goat anti-mouse
gG (HAF007) from R&D Systems, and goat anti-rabbit
gG (#31460) from Thermo Fisher Scientific (Rockford,
llinois). Immunoblots were quantified and normalized to
APDH levels using ImageQuant TL v2005 software
ersion 7.0 (GE Healthcare, Little Chalfont, United King-
om), expressed as mean  SD.
orthern blot analysis. RNA was isolated from HeLa and
UVECs treated with vehicle (phosphate-buffered saline
ith 0.1% bovine serum albumin) or with 100 ng/ml
nterferon- using TRIzol reagent (Life Technologies, Bur-
ington, Ontario, Canada), according to the manufacturer’s
nstructions. Fifteen micrograms of RNA was size fraction-
ted by polyacrylamide gel electrophoresis, transferred to a
ylon membrane, and then probed with CDKN2A (clone
954155, Open Biosystems, Lafayette, Colorado) or
DKN2B (clone 4871014) radiolabelled with dCT32[P]
sing the random primers technique (Agilent Technologies,
a Jolla, California). Images were revealed using a
hosphor-storage screen and a Storm 860 molecular imager
GE Healthcare Life Sciences, Baie D’Urfe, Quebec,
anada).
esults
nterferon- markedly increases p16 and p15 protein
levels. LCLs are Epstein-Barr virus transformed B lym-
phocytes that remain in a proliferative state because
p16INK4A (CDKN2A) expression is repressed by the
Epstein-Barr virus nuclear antigens 3A and 3C (11,12). The
ability to immortalize B lymphocytes from many individuals
of different ancestry and to ascertain by high throughput the
genotypes of common genetic variants has been a corner-
stone of the International HapMap project (13). Because
the genotype of common variants, including the
rs10757278, are known or can be imputed for these cells
lines, and because these cells maintain a low level of p16
expression, we tested whether interferon- can activate the
expression of p16 and p15 and whether the 9p21.3 CAD
risk genotype influences this response.
LCLs for each 9p21.3 genotype were selected from the
HapMap database and purchased from the Coriell Institute
for Medical Research. Where the genotype for the STAT1-
responsive sequence disrupted by rs10757278 was not
known, it was imputed using linked flanking SNPs (D= 
1.0, r2 0.8) (Table 1). All cell lines were genotyped for the
rs10757278 SNP by PCR amplification and direct sequenc-
ing, and the genotypes agreed with the imputation. LCLs
treated with interferon- markedly increased the levels of
p15 and p16, as revealed by immunoblot (Fig. 1A). We
were unable to detect the alternative product of the
CDKN2A gene, p14ARF (data not shown). Importantly, of
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January 15, 2013:143–7 Mechanisms of Coronary Risk and 9p21.3the 16 LCLs tested (5 homozygous nonrisk, 5 heterozy-
gotes, and 6 homozygote risk for the 9p21.3 genotype),
regardless of 9p21.3 CAD genotype, no substantial differ-
ence was observed in the level to which interferon-
increased p15 (n  16) and p16 (n  12) expression
Fig. 1B).
The response to interferon- was also tested in other cell
types (Fig. 2A). In HAoSMCs heterozygous for the
rs10757278 genotype (as well as for rs1333045, rs1333048,
and rs133049), a robust elevation of p15 and p16 was
observed. By contrast, p15 and 16 levels were not affected by
interferon- treatment in HUVECs homozygous for the
onrisk genotype of 9p21.3 (rs1333048), despite a clear
ctivation of pSTAT1. Similar to the LCLs, the cell lines
EK293 (homozygous for the 9p21.3 rs1333048 risk allele)
nd HeLa (heterozygous for rs1333048) also increased p16
nd p15 levels in response to interferon-. To determine
hether interferon- treatment affects CDKN2A and
CDKN2B mRNA levels, we performed Northern blot
analysis of HUVECs and HeLa cells (Fig. 2B). Interferon-
did not elevate CDKN2A levels in HeLa cells, and
CDKN2A mRNA was not detected in HUVECs. On the
ther hand, a slight increase in CDKN2B was detected in
HeLa cells treated with interferon-, whereas there was no
change in CDKN2B mRNA in HUVECs.
Discussion
A recent study claimed that the mechanism whereby the
9p21.3 risk locus operates is by impairing the response to
interferon- (8). These authors reported that interferon-
markedly reduced the mRNA levels of the cyclin dependent
kinase inhibitor p15 (encoded by CDKN2B) in HeLa and
HUVECs (cells that are heterozygous for the 9p21.3 risk
Imputation and Sequence Confirmation of rs107Lymphoblastoid Cells Us d in This StudyTable 1 Imputatio and Sequence ConfirmaLymphoblastoid Cells Used in This S
LCL ID rs944797 rs2383207 rs153
GM10835 CC GG C
GM11992 CC GG C
GM11995 CC GG C
GM12282 CC GG C
GM11840 CT AG C
GM12234 CT AG C
GM12817 CT AG C
GM12864 CT AG C
GM12872 CT AG C
GM12873 CT AG C
GM12003 TT AA T
GM12057 TT AA T
GM12283 TT AA T
GM12336 TT AA T
GM12775 TT AA T
GM12890 TT AA T
*Imputed genotypes using flanking single nucleotide polymorphisms,
were confirmed by sequencing.
LCL  lymphoblastoid cells.locus) (8). However, using the same dose of interferon-(100 ng/ml), we observed increased expression of p15 in all
cell types examined except HUVECs, where the levels were
unchanged. Importantly, when tested in 16 different LCLs,
the 9p21.3 risk locus did not affect the response of p15 and
p16 to interferon-y. Thus, it seems unlikely that the
rs10757278 SNP that disrupts a STAT1-responsive ele-
ment in the 9p21.3 risk locus is sufficient to affect the
activation of p15 and p16 in response to interferon-y. It is
worthwhile pointing out that whereas Harismendy et al. (8)
measured CDKN2B mRNA by reverse-transcription PCR,
e measured protein levels of p15 and p16 by immunoblot.
urthermore, Northern blot analysis of mRNA from HeLa
ells (heterozygote for 9p21.3) showed no change in
DKN2A mRNA and a slight increase in CDKN2B
RNA. In addition, our HUVECs were homozygous for
he nonrisk allele of 9p21.3, thus should have responded
obustly to interferon-, but showed no change in CDKN2B
RNA levels. Both results contrast with the reduced
xpression reported by Harismendy et al. Our study is
onsistent with a previous report that also found that p16,
ut not p14ARF, is up-regulated by interferon- in human
cells (14). Furthermore, interferon- was reported to in-
crease the translation of the ICAM1 protein by a STAT1-
dependent mechanism that suppresses miR-221 expression
(15). Thus, in some instances, interferon- can increase
protein translation, and in the case of p16, this effect appears
to be independent of the mRNA levels. Our study indicates
that the mechanism whereby the 9p21.3 risk allele contrib-
utes to CAD is not by blocking the activation of p15 or p16
by interferon-.
Multiple enhancer-like sequences are present within the
9p21.3 risk locus that could influence the expression of
flanking genes (6–8). Under basal conditions, in nontrans-
8 Genotypes of thef rs10757278 Genotypes of the
rs10757278 rs1333048 rs1333049
GG CC CC
GG CC CC
GG CC CC
GG* CC CC
AG AC CG
AG AC CG
AG* AC CG
AG AC CG
AG AC CG
AG AC CG
AA* AA GG
AA AA GG
AA* AA GG
AA* AA GG
AA* AA GG
AA* AA GG
by relative position on chromosome 9, with a D’  1 and an r2  0.85727tion o
tudy
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Mechanisms of Coronary Risk and 9p21.3 January 15, 2013:143–7and/or p16 conferred by the enhancer sequences at the
9p21.3 locus. However, these basal differences may be
masked by the repression of the CDKN2A locus by the
Epstein-Barr virus nuclear antigens 3A and 3C (11,12). Our
choice of LCLs was not to test basal differences in p15 and
p16 expression but rather to test whether the 9p21.3
genotype influences the response of these genes to
interferon-.
The hypothesis that the 9p21.3 locus confers a differential
response to interferon- is clearly not supported by our data,
ecause we observed increased p15 and p16 expression
egardless of genotype. The disease process itself may
nfluence the activity of the enhancer sequences at 9p21.3.
any other growth factors and cytokines are produced at
therosclerotic lesions (16) and could have differential effects
t other enhancer elements that contain functional SNPs,
ike the one we identified at rs1333045 (6). In addition,
any SNPs at the 9p21.3 locus could be the functional
ulprits and may act together to modulate gene expression.
or example, the linked polymorphism rs10811656 located
nly 4 bp from the putative STAT1 binding sequence
rs10757278) disrupts a putative TEAD factor binding site
CATTCCGCATTCTG) (17), but it is not known
hether this element is functional or influences enhancer
ctivity. TEAD factors are known to regulate cell cycle
rogression (18,19), and it will be interesting to see whether
Figure 2 Effect of Interferon- on p15 and
p16 Levels in Different Cell Types
(A) Results of immunoblot analysis of protein extracts from human primary aor-
tic smooth muscle cells (HAoSMCs) (9p21 heterozygote) and human umbilical
vein endothelial cells (HUVECs) (9p21 homozygote nonrisk), as well as from
HEK293 (homozygote risk) and HeLa (heterozygote) cells are shown. GAPDH
was not affected by interferon- and was used as a loading control. (B) North-
ern blot analysis shows no or only modest increases in CDKN2A and CDKN2B
levels in HUVECs and HeLa cells in response to interferon- (INF-). 28S and
18S RNA signals confirmed equal loading of 15 g of RNA per lane.Figure 1 Interferon- Activates p16 and p15
Expression Regardless of 9p21.3 Genotype
(A) Lymphoid cells (LCLs) homozygous (Homo) nonrisk (n  5), heterozygote (Het)
(n  5), or homozygote risk (n  6) for the 9p21.3 genotypes were treated with
vehicle or 100 ng/ml recombinant human interferon- (INF-) for 24 h and then
harvested for immunoblot analysis (representative results). Antibody to phosphory-
lated serine 727 (p-Ser 727) of Stat1 confirmed activation by interferon-. Num-
bers below lanes are unique identifiers for the LCLs. (B) Quantification of the
response to interferon- showed no substantial difference between genotypes for
p15 (n  5 per genotype) or p16 (n  3 per genotype). Fold induction is
expressed as mean  SD.
147JACC Vol. 61, No. 2, 2013 Almontashiri et al.
January 15, 2013:143–7 Mechanisms of Coronary Risk and 9p21.3differential binding of TEAD factors might account for the
risk of coronary artery disease in future studies. Of the more
than 100 SNPs linked to the 9p21.3 locus, exhaustive
functional characterization would be required and is beyond
the scope of the present study. Thus, the precise mechanism
whereby the 9p21.3 locus contributes to the risk of CAD
remains to be elucidated.
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